J Infect Dis by Shrivastava, Ritu et al.
Importance of Public-Private Partnerships: Strengthening 
Laboratory Medicine Systems and Clinical Practice in Africa
Ritu Shrivastava1, Renuka Gadde2, and John N. Nkengasong1
1International Laboratory Branch, Division of Global HIV/AIDS, Center for Global Health, Centers 
for Disease Control and Prevention, Atlanta, Georgia
2Becton, Dickinson, and Company, Franklin Lakes, New Jersey
Abstract
After the launch of the US President’s Emergency Plan for AIDS Relief in 2003, it became evident 
that inadequate laboratory systems and services would severely limit the scale-up of human 
immunodeficiency virus infection prevention, care, and treatment programs. Thus, the Office of 
Global AIDS Coordinator, Centers for Disease Control and Prevention, and Becton, Dickinson, 
and Company developed a public-private partnership (PPP). Between October 2007 and July 2012, 
the PPP combined the competencies of the public and private sector to boost sustainable 
laboratory systems and develop workforce skills in 4 African countries. Key accomplishments of 
the initiative include measurable and scalable outcomes to strengthen national capacities to build 
technical skills, develop sample referral networks, map disease prevalence, support evidence-based 
health programming, and drive continuous quality improvement in laboratories. This report details 
lessons learned from our experience and a series of recommendations on how to achieve 
successful PPPs.
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Since the early 2000s, global collective action has expanded access to antiretroviral therapy 
for people living with human immunodeficiency virus (HIV), with or without AIDS (HIV/ 
AIDS), in developing countries [1].As part of the global response, government agencies and 
nongovernmental organizations—including the US President’s Emergency Plan for AIDS 
Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria—
developed new and innovative funding mechanisms to support access to medicines [2]. 
Although many programs addressed the urgent need for antiretroviral therapy in sub-Saharan 
Africa [3, 4], as of 2005 none addressed the weak laboratory systems that hamper health 
professionals’ ability to track diseases and deliver the most appropriate treatment to their 
patients [5–7]. As care and treatment efforts expanded, the gaps and shortcomings in 
laboratory systems became abundantly clear and were seen as an issue that could not be 
solved by either the public or private sector alone [8–10].
Funding from PEPFAR and the Global Fund to Fight AIDS, Tuberculosis, and Malaria 
created unprecedented opportunities to improve laboratory systems, and public-private 
partnerships (PPPs) are an innovative approach for building sustainable laboratory systems 
in resource-limited countries [6, 11]. Despite the enormous progress made in the HIV/AIDS 
arena, the global recession precipitated a funding crisis that now threatens to undermine 
these hard-fought gains [1, 8, 12, 13]. New and sustainable approaches should be assessed to 
optimize methods for improving laboratory systems.
The combination of the individual strengths of the private and public sectors is one way to 
establish a strong foundation for sustainable change and success [14–16]. Private sector 
engagement and PPPs play a critical role for PEPFAR by sharing responsibility for 
achieving an AIDS-free generation and meeting the sustainable development goals [10, 17–
19]. Although there are several examples of PPPs improving health services globally [20–
23], few address laboratory networks [24, 25]. PPPs are, therefore, needed in this area to act 
collectively to expand and enhance existing laboratory networks to improve patient care and 
treatment services [11].
This supplement reports the overall impact of the PPP between Becton, Dickinson, and 
Company (BD) and PEPFAR on HIV/AIDS and tuberculosis programming through 
laboratory-strengthening activities in Uganda, Ethiopia, Mozambique, and South Africa. The 
PPP contributed to national capacity development in the areas of building technical skills, 
developing guidelines, planning sample referral networks, mapping disease prevalence, 
implementing evidence-based health programming, and continuous quality improvement in 
laboratories, all of which are goals shared by these countries and PEPFAR.
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A RAPID RESPONSE TO A COMPLEX PROBLEM: THE BD-PEPFAR PPP
In 2007, the Office of the US Global AIDS Coordinator of the US Department of State, the 
Centers for Disease Control and Prevention (CDC), and the global medical technology 
company BD signed a memorandum of understanding. This memorandum promoted sharing 
each organization’s respective strengths, experiences, methods, and competencies to pursue 
a public-private partnership focused on supporting specific laboratory-system-strengthening 
projects relevant to the goals of ministries of health (MOHs) and PEPFAR for prevention 
and treatment of HIV/AIDS. PEPFAR defines PPPs as collaborative endeavors that combine 
resources from the public sector with resources from the private sector to accomplish HIV/
AIDS prevention, care, and treatment goals [26]. The key aspect of a PPP is that the private 
sector partner must be contributing a 1:1 ratio of financial contributions, in-kind 
contributions, or intellectual property. The BD-PEPFAR PPP was implemented at an 
estimated shared cost of $18 million, which represents dollars spent and products provided, 
as well as donated time and services.
Ethiopia, Kenya, Mozambique, South Africa, and Uganda were chosen on the basis of their 
political support and readiness to provide leadership in the PPP. In-country projects were 
identified on the basis of the priorities that each country’s MOH highlighted in its national 
laboratory strategic plan.
As the lead governmental partner in the BD-PEPFAR PPP, the CDC contributed its expertise 
in disease prevention and detection, patient monitoring, and surveillance. Laboratory-
strengthening PPPs are under the purview of CDC laboratory directors in country offices. 
Acting in its role as the implementing agency, the International Laboratory Branch (ILB) 
within the Division of Global HIV/AIDS (the addition of “Tuberculosis” to the end of the 
division name is under proposal) in the Center for Global Health of the CDC drew on its 
staff to provide technical assistance and guidance in cutting-edge technologies and 
laboratory-system strengthening. Experts from the head-quarters of BD and the International 
Laboratory Branch met twice yearly for strategic planning, intercountry coordination, and 
technical assistance. Both BD and the CDC deployed dedicated staff who tapped into their 
home organizations for additional support, as well as the expertise of staff in the field.
The in-country CDC laboratory director supported BD staff in introducing the PPP to MOH 
officials. These introductions facilitated development of work plans for priority topics. These 
work plans were used by BD to identify competent BD Global Health Fellows from its 
worldwide workforce of experts, to assist local staff. Between 2009 and 2012, 75 fellows 
were deployed in the field for short-term assignments, observing, assessing, training, and 
mentoring laboratory personnel. A job description and rigorous interview process for 
selecting staff were developed by BD. Fellows were required to have 1 or more years of 
service with BD and were matched by their area of expertise to country-specific needs. Staff 
were drawn from a wide selection of competencies and included logistics coordinators, 
medical technicians, microbiologists, phlebotomists, and quality consultants. The fellows’ 
orientation focused on all aspects of the project, ranging from country-specific cultural 
sensitivities to clarifying roles and responsibilities for the assignment.
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The in-depth methods and programmatic results of this PPP are reported in the 
accompanying reports in this supplement. This report summarizes the results from a 
management perspective and focuses mainly on identifying the practices integral to the 
success of the PPP. Recommendations are also provided to benefit multinational healthcare 
companies and local decision makers aspiring to form their own PPPs.
THE IMPACT OF THE PPP
BD and PEPFAR have successfully applied the established practice of PPP for the first time 
to the world of laboratory medicine. This PPP demonstrates a measurable, scalable, 
evidence-based model to multiply the individual strengths and competencies of the public 
and private sectors to fortify the lagging world of laboratory medicine in resource-limited 
settings.
CHALLENGES AND LESSONS LEARNED FOR COUNTRIES AND PRIVATE 
ENTITITES ASPIRING TO ENGAGE IN A PPP
An independent third-party evaluation documented the challenges and lessons learned 
during the 5 years of coordinating and managing the BD-PEPFAR PPP (focusing on 2007–
2012) [27]. This information was presented at a conference in Pretoria, South Africa, which 
was attended by participants from the Office of the US Global AIDS Coordinator, the CDC, 
BD, and leadership from all the countries involved in the PPP. We hope that the following 
lessons will benefit countries, international agencies and private entities who are either 
already engaged in a PPP or intend to engage in one in the future.
Maintain Strong Channels of Communication
Given several organizations involved in the execution and implementation of country-
specific work plans, there was a strong need to explicitly define the roles and responsibilities 
of each of the partners, and communication between partners was a key to the success of the 
PPP. Long distances and physical boundaries should not deter collaboration; partners must 
come together regularly to operate as virtual teams at predefined intervals throughout the 
project.
Define Formal Monitoring and Evaluation Arrangements
All countries and private companies preparing to embark on a PPP should ensure that 
stakeholders formally define and agree on monitoring and evaluation metrics before starting 
the intervention. This will ensure that baseline data are collected prior to the PPP’s 
contribution, helping attribute success to the respective partners after the intervention. These 
arrangements include but are not limited to data collection, management, analysis, 
interpretation, and dissemination.
Establish Mechanisms to Capture Matching Funds
Stakeholders must agree on the mechanism to capture the allocation of matching funds for 
the PPP before starting the project.
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Form In-country PPP Coordination Units
The CDC laboratory directors stationed in countries recommended that all parties form an 
in-country coordination unit/ steering committee or its equivalent to efficiently manage and 
provide oversight and guidance for the PPP.
Build Sustainability Through Continuous Technical Support
The PPP was designed to operate through a series of short-term interventions. The BD 
clinical staff provided technical assistance in the field for a maximum duration of 3 weeks; 
however, teams returned multiple times until the project was completed. Some in-country 
staff preferred longer visits to ensure sustainability and gain greater understanding of the 
local context. Several measures were taken by the partners to address these issues, such as 
strengthening orientation by partner organizations, setting up a unique dedicated email box 
for ongoing mentorship, and undertaking a thorough transfer of knowledge between the PPP 
fellows and in-country laboratory staff.
Take Local Considerations Into Account
Understanding the local context is key to effective country engagement, facilitation, and 
transferring knowledge and skills. If this local understanding is not present, barriers can 
arise, as was seen in Ethiopia, where the local experts recommended that trainings be offered 
in a local official language, including a local trainer as part of the team, to mitigate language 
barriers. Notably, in Mozambique, the BD trainers working with the MOH and other key 
stakeholders were required to be fluent in Portuguese, which contributed significantly to the 
success of the program. The global nature of BD’s workforce was leveraged by deploying 
staff from the BD Brazil sites to work in Mozambique.
Joint Review of Accomplishments
The country teams recommended that, to ensure sustained success, all stakeholders and 
decision makers should jointly review accomplishments and lessons learned. This review 
should occur annually at a minimum.
FACTORS NEEDED FOR A SUCCESSFUL PPP
Having little to rely on for precedent, the BD-PEPFAR PPP has been a continual work in 
progress, requiring resourcefulness and flexibility from all stakeholders in response to 
persistent and changing demands. Several success factors have, however, emerged as the 
PPP has evolved. Table 2 summarizes our FOCUSED recommendations, which can 
contribute to the success of PPPs for countries already engaged in a PPP or aspiring to 
engage in one in the future.
F = Frame Clear Goals, Roles, and Responsibilities for Partners
PPPs that begin with common goals are known to be successful [28]. In this case, the 
partners, BD and the CDC (on behalf of the OGAC), were united by an understanding that, 
within the PPP, their common goal would be to promote laboratory strengthening in 
PEPFAR-supported countries. The partners outlined broad goals and objectives in a 
memorandum of understanding. This provided a shared context for countries that then 
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developed a country-specific work plan based on their own national laboratory strategic 
plan. Common goals enabled partners to outline roles and responsibilities, thus improving 
coordination. Specific and measurable objectives propelled partners into planning, 
organizing, and coordinating the initial phase of engagement between the 2 partners.
O = Operate With Open and Frequent Communication to Build Trust
In-country CDC laboratory directors leveraged their existing relationships with the MOH 
and local champions, opening doors for BD’s Global Health Fellows. The in-country CDC 
presence played an indispensable role in engaging local champions for the PPP (eg, the 
Ethiopian Public Health Institute, the Ugandan National Tuberculosis Reference Laboratory, 
and the African Centre for Integrated Laboratory Training). These preexisting relationships 
built trust and facilitated coordination among partners, enabling sharing and timely planning 
and execution of program activities. Mutual trust was a key ingredient for success.
C = Communicate Conflicts of Interest in Early Stages of Engagement
It is important to disclose potential conflicts of interest early on to ensure transparency of the 
respective partners’ underlying motivations. The interests of all organizations and feasibility 
of matching their expectations should be discussed openly in the early stages of engagement. 
If it appears that one of the partners has an agenda to promote its own commercial interest in 
addition to the common goal on which the partnership is built, then the purpose of the 
partnership should be revisited. If the interests still do not align, then the partners should 
consider abandoning the partnership while still in the preplanning phases. In this PPP, the 
memorandum of understanding made it clear that all partners would work together to 
address common goals. Potential conflicts of interest were addressed up front to avoid any 
confusion over BD’s commercial goals versus those of the PPP.
U = Utilize the Strengths of Other Organizations to Enrich the PPP
The complexity of healthcare systems demands multifaceted analyses and solutions. For 
example, one of the problems facing the tuberculosis program in Uganda was the difficulty 
of receiving and tracking multidrug-resistant tuberculosis samples and in providing accurate 
results to patients. To address this issue, BD’s staff worked with external partners such as 
Direct Relief International to learn about powerful geographic information systems that 
could help analyze and interpret data to detect disease patterns, trends, and relationships. In 
turn, BD worked with the CDC and the Uganda MOH to train local laboratory workers how 
to use software and analyze data and then teach these skills to others, thus continuing the 
cycle of learning. The result was a highly skilled team of specialists armed with the tools 
and data needed to continually refine and optimize their specimen handling and result 
reporting infrastructure. Today, sites that have incorporated geographic information systems 
can, with a few mouse clicks, track the entire cycle of specimen collection and testing and 
can report results accurately and efficiently to patients. Through innovative thinking, the 
PPP found a way to address the problem and turn it into an opportunity to boost the existing 
system with new technology.
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S = Share Best Practices and Foster Country Ownership to Ensure Sustainability
The BD-PEPFAR PPP was established over an initial 5-year time frame, based on early 
understanding that driving sustainable change and skill-based training would not happen 
effectively in the short term. The core goal of the PPP was to comprehensively strengthen 
local health systems by working hand in hand with laboratory technicians and clinicians in-
country. The partners shared the philosophy that the return on this investment was the long-
term impact of establishing strong healthcare systems, sharing best practices, and ultimately 
fostering country ownership to significantly diminish the disease burden of HIV/AIDS and 
tuberculosis.
E = Evaluate and “Measure What Matters” Using an Outcomes-Based Approach
Stakeholders should work together to recommended metrics to measure progress, and 
success should be agreed on before starting the intervention. In the case of the BD-PEPFAR 
PPP, the partners recommended that monitoring and evaluation should be an ongoing effort 
and not a one-time event. They also recommended engaging a third-party organization 
whose focus was monitoring and evaluation to get this done in a timely and effective 
manner.
D = Deploy the Right Human Resources; People Make All the Difference
The PPP was managed by dedicated staff at both the head offices and local-level offices of 
BD and the CDC, with support and involvement from senior leadership within each entity.
The CDC’s strength lies in its expertise in disease prevention and detection, surveillance, 
and patient monitoring [29]. It leveraged the competencies of staff at the International 
Laboratory Branch for technical assistance in countries. Locally, the CDC used its in-
country presence, deep knowledge of the operating environment, and existing strong 
relationships with the MOHs to facilitate and implement the PPP.
BD offered expertise as a medical technology company that serves healthcare institutions, 
clinical laboratories, industry, and the general public, with offices in >50 countries 
worldwide. The company has a long history of innovation, with the mission “to help all 
people live healthy lives.” BD created a system for recruiting the right people from its pool 
of experts to provide training in the field.
DISCUSSION
The success of the PEPFAR program in Africa has challenged conventional wisdom on how 
global health is pursued. It has supported treatment of 7.7 million patients living with HIV/ 
AIDS, while working to strengthen health and laboratory systems [1–3, 30]. Alongside this 
success, PEPFAR has worked in close collaboration with the public and private sectors, such 
as the CDC, MOHs, and BD, to establish PPPs. By combining the strengths, experiences, 
methods, and resources across sectors, these PPPs have been successful in supporting 
laboratory-strengthening projects relevant to PEPFAR’s core goals for HIV/AIDS 
prevention, treatment, and care.
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The BD-PEPFAR PPP has had some key successes influencing patient care, such as 
returning laboratory results to physicians and patients in a timelier manner, a critical step in 
the care process. It has been reported that only between 35% and 88% of results reach 
patients in time to promptly start treatment [31].This PPP helped reduce turnaround times in 
Uganda, an achievement later replicated in Ethiopia. In Ethiopia, using Ethiopian Postal 
Service Enterprise, the PPP standardized and streamlined specimen logistics to support 
laboratory network. In Addis Ababa, the results of the PPP reduced the turnaround time 
(measured from collection to delivery of results) for ART specimens from 7 to 2 days—a 
71% decrease—and, in the Amhara region, reduced turnaround time from 10 to 5 days—a 
50% decrease. In Uganda, referrals from persons with presumptive multidrug-resistant 
tuberculosis increased >10-fold, with 94% of specimens reaching the National Tuberculosis 
Reference Laboratory within the country’s established turnaround time target of 3 days. 
Turn-around times for receiving specimens and reporting results to patients receiving 
antiretroviral therapy are used as a benchmark for laboratory performance [32]. Faster 
turnaround times have an important role in curtailing costs incurred by the patient and 
government [11]. These accomplishments decreased the time needed to initiate treatment, 
which has been shown to reduce opportunistic infections, encourage viral suppression, and 
potentially limit further transmission [33, 34].
A stronger workforce is key to achieving a nation’s public health goals; however, it is a 
critical weakness in resource-limited settings [35]. In South Africa, the PPP worked to solve 
this crisis through innovative training programs for tuberculosis, eventually reaching 16 
countries. In Mozambique, the PPP was instrumental in supporting the MOH to appoint 
dedicated personnel to lead the implementation of newly established quality assurance 
efforts, thus building local capacity and reducing the costs of audits and need for technical 
assistance from foreign laboratory professionals.
The early success of the PPP inspired both partners to build a series of collaborations, such 
as the BD-PEPFAR Safer Blood Collection Partnership, which has been implemented in 
Kenya, Tanzania, Zambia, and Kyrgyzstan. A new laboratory partnership, Labs for Life, was 
established in 2012 between BD and PEPFAR. This expanded PPP will run through 2017 
with the support of $20 million in funding and includes 2 new countries, India and Kenya.
From BD’s perspective, there is recognition that PPPs are a critical platform for the 
company’s global health initiatives, paving the way to building and upgrading clinical 
practices that influence human lives. The results-driven approach drives further investment 
in these programs. For MOHs, PPPs provide much needed technical expertise, access to 
critical technologies and supplies, and creative, flexible solutions to seemingly intransigent 
problems.
The success of this PPP indicates that this model is scalable and expandable to other 
countries with similar resources for health-systems strengthening. It also demonstrates that 
effective collaboration is possible and necessary between the public and private sectors to 
solve complex health programs.
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Table 1
Outcomes of Public-Private Partnership Between Becton, Dickinson, and Company and the Centers for 
Disease Control and Prevention in Select Countries Aided by the US President’s Emergency Plan for AIDS 
Relief: 2007–2012
Country,
Authorsa Key Activity Key Outcome(s)
Ethiopia, Kebede et al Establishment of standardized, streamlined 
specimen logistics, using EPSE to support 
laboratory network
Addis Ababa reduced TAT collection to delivery of results) for ART 
specimens from 7 to 2 d (71% decrease); the Amhara region reduced 
TAT time from 10 to 5 d (50% decrease)
Kenya, Kimani et al Roll out of safe phlebotomy partnership, 
including integration of safe phlebotomy 
practices into preservice training
91 HCWs were trained in phlebotomy; average performance 
increase: 41% (95% CI, 29.3%–53.5%; P < .001)
Mozambique, Skaggs 
et al
Establishment of NLQA program to 
facilitate stepwise quality improvement of 
laboratory service
MOH appointed designated quality assurance officers to work with 
selected laboratories to steer them toward accreditation
South Africab Training of 150 participants from 16 sub-
Saharan Africa countries at ACILT in 
tuberculosis diagnostics
Developed more-competent health workforce for tuberculosis 
diagnostics; in 2010, 43 participants had 57% improvement in 
tuberculosis culture and identification test scores
Uganda, Joloba et al Training and development of standardized 
tuberculosis specimen transport network
10-fold increase in referrals of patients with presumptive multidrug-
resistant tuberculosis; 94% of submitted specimens reached NTRL 
within 3 d
Abbreviations: ACILT, African Centre for Integrated Laboratory Training; ART, antiretroviral therapy; CI, confidence interval; EPSE, Ethiopian 
Postal Service Enterprise; HCW, healthcare worker; MDR, multidrug-resistant; MOH, ministry of health; NLQA, National Laboratory Quality 
Assurance; NTRL, National TB Reference Laboratory; TAT, turnaround time.
a
Found elsewhere in this supplement, unless otherwise indicated.
b
Not presented in this supplement.
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Table 2
FOCUSED Recommendations for a Successful Public-Private Partnership
Frame clear goals, roles, and responsibilities for partners.
Operate with open and frequent communication to build trust.
Communicate conflicts of interest in early stages of engagement.
Utilize the strengths of other organizations to enrich the program.
Share best practices and foster country ownership to ensure sustainability.
Evaluate and “measure what matters” using an outcomes-based approach.
Deploy the right human resources; people make all the difference.
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